Kazia Therapeutics vs Lyell Immunopharma
KZIA and LYEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KZIA and LYEL compare
Lyell Immunopharma grew revenue faster over the last twelve months (−55.0% versus −98.2% for Kazia Therapeutics).
Kazia Therapeutics keeps more of each dollar of sales as profit, with a net margin of −49291% compared with −920285% at Lyell Immunopharma.
Lyell Immunopharma scores higher on the StockData Score (6 against 1 for Kazia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KZIA | LYEL |
|---|---|---|
| Size and price | ||
| Market cap | – | $335M |
| Share price | $5.31 | $13.67 |
| Change, 1 year | −15.3% | −19.3% |
| Change, 5 years | −98.9% | −92.7% |
| Beta (5Y) | 4.08 | 1.37 |
| Employees | 14 | – |
| StockData Score | ||
| Total score | 1 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 12407× |
| P/B | – | 1.4× |
| FCF yield | – | −40.0% |
| Growth | ||
| Revenue growth (TTM) | −98.2% | −55.0% (better) |
| Revenue growth, 5Y average | – | −65.9% |
| Profitability | ||
| Operating margin | – | −949981% |
| Net margin | −49291% (better) | −920285% |
| FCF margin | – | −496189% |
| Return on equity | – | −93.3% |
| Return on invested capital | – | −782% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 2.87 | 5.36 (better) |
| Altman Z-score | – | −7.05 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.45% | 48.9% |
| Held by insiders | 0.29% | 45.0% |
| Insider net buying, 12 months | – | $74.4M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | – | 10.5% |
Go deeper
- KZIA stock overview
- KZIA income statement
- KZIA valuation and score
- LYEL stock overview
- LYEL income statement
- LYEL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.